BRAF V600 Mutation Positive Melanoma
1 clinical trials · Condition
◉ Watch BRAF V600 Mutation Positive Melanoma
| Record | Firm | Date |
|---|---|---|
| A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma (NCT06337617) | Novartis Pharmaceuticals | 2022-05-10 |
Track BRAF V600 Mutation Positive Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.